Michael Ehlers is betting $40M that an AI outfit has figured out how to beat the blockbuster IL-2 challenge
Sanofi was so intrigued by the prospect of figuring out a breakthrough on IL-2 in cancer that Paul Hudson recently engineered a $2.5 billion acquisition of Synthorx to add it to the pipeline. Now Michael Ehlers believes he’s found the key to the IL-2 challenge, and he’s steering a straight course into a human study — at a much lower price.
This morning the ex-Biogen R&D chief and current CSO at ATP (what had been Apple Tree Partners) unveiled a deal to partner with Biolojic Design on an antibody their computational design team came up with that binds directly to naturally occurring IL-2 and drags it to low affinity effector T cells and away from the Treg crowd of bad actors.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,400+ biopharma pros reading Endpoints daily — and it's free.